Cargando...
Bone Is a Target for the Antidiabetic Compound Rosiglitazone
Rosiglitazone is an FDA-approved oral antidiabetic agent for the treatment of type 2 diabetes. This compound improves insulin sensitivity through the activation of the nuclear receptor, peroxisome proliferator-activated receptor-γ (PPAR-γ). In addition to sensitizing cells to insulin, the PPAR-γ2 is...
Gardado en:
| Main Authors: | , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
2003
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC1855213/ https://ncbi.nlm.nih.gov/pubmed/14500573 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/en.2003-0746 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|